The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma

Li,Yan; Zhou,Wanqi; Wei,Langli; Jin,Jing; Tang,Ke; Li,Chao; Teh,Bin  Tean; Chen,Xiaoguang

doi:10.3892/ijo.2012.1633

The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma

Authors:
- Yan Li
- Wanqi Zhou
- Langli Wei
- Jing Jin
- Ke Tang
- Chao Li
- Bin Tean Teh
- Xiaoguang Chen
View Affiliations

Affiliations: State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China, NCCS-VARI Translational Research Laboratory, National Cancer Center, Singapore 169610, Republic of Singapore
Published online on: September 20, 2012 https://doi.org/10.3892/ijo.2012.1633
Pages: 2139-2149

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aurora kinases have been shown to be involved in the regulation of the cell cycle and are related to tumor progression. This suggests the possibility that they can serve as new anticancer targets for tumor treatment. However, the important roles that Aurora kinases and their signaling pathway play in renal cell carcinoma (RCC) are not fully understood and addressed to date. In this study, we aimed to address these questions. We observed that downregulation of Aurora kinases induced by AurA miRNA, AurB miRNA or VX680 could inhibit proliferation and metastasis, induce G2/M phase arrest in clear cell renal cell carcinoma cells and exert antitumor activity in an SN12C xenograft model. We also show that either silencing of Aurora kinases or treating the cells with VX680 could downregulate the expression of cdc25c and cyclin B/cdc2, upregulate the expression of p-cdc2 (Tyr15) via blocking the activity of ERK. All these changes may contribute to inhibition of proliferation, metastasis and G2/M arrest in ccRCC. In summary, we proved that both Aurora kinases A and B are key elements of tumor growth regulation, and inhibition of Aurora kinases may contribute to blocking ccRCC progression. We conclude that Aurora kinases could be potential therapeutic targets in the management of renal cell carcinoma.

View Figures

View References

1.	Bensalah K and Patard JJ: Kidney cancer in 2010: drugs, surgery and survival in RCC. Nat Rev Urol. 8:66–68. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Chowdhury S and Choueiri TK: Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev Anticancer Ther. 9:373–379. 2009. View Article : Google Scholar
3.	Chowdhury S, Matrana MR, Tsang C, et al: Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am. 25:853–869. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Keen N and Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 4:927–936. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Tyler RK, Shpiro N, Marquez R and Eyers PA: VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle. 6:2846–2854. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Yang H, He L, Kruk P, et al: Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 119:2304–2312. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Dutertre S, Cazales M, Quaranta M, et al: Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci. 117:2523–2531. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Gizatullin F, Yao Y, Kung V, et al: The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res. 66:7668–7677. 2006. View Article : Google Scholar
9.	Merk BC, Owens JL, Lopes MB, et al: STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer. 11:1842011. View Article : Google Scholar : PubMed/NCBI
10.	Cloos J, Temmink O, Ceelen M, et al: Involvement of cell cycle control in bleomycin-induced mutagen sensitivity. Environ Mol Mutagen. 40:79–84. 2002. View Article : Google Scholar : PubMed/NCBI
11.	Temmink OH, Prins HJ, van Gelderop E and Peters GJ: The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer. 96:61–66. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Li Y, Zhang ZF, Chen J, et al: VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res. 2:296–308. 2010.PubMed/NCBI
13.	Huang D, Ding Y, Luo WM, et al: Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res. 68:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Harrington EA, Bebbington D, Moore J, et al: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 10:262–267. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Teicher BA: Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res. 14:1610–1617. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Suzuki T, Urano T, Miki Y, et al: Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 98:644–651. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Perdiguero E and Nebreda AR: Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle. 3:733–737. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Singh SV, Herman-Antosiewicz A, Singh AV, et al: Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem. 279:25813–25822. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Pearson G, Robinson F, Beers Gibson T, et al: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 22:153–183. 2001.PubMed/NCBI
20.	Lee SJ, Park K, Ha SD, et al: Gleditsia sinensis thorn extract inhibits human colon cancer cells: the role of ERK1/2, G2/M-phase cell cycle arrest and p53 expression. Phytother Res. 24:1870–1876. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Meraldi P, Honda R and Nigg EA: Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 14:29–36. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Gautschi O, Heighway J, Mack PC, et al: Aurora kinases as anticancer drug targets. Clin Cancer Res. 14:1639–1648. 2008. View Article : Google Scholar : PubMed/NCBI
23.	Lee EC, Frolov A, Li R, et al: Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res. 66:4996–5002. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Lee YM, Ting CM, Cheng YK, et al: Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells. Cancer Lett. 268:295–307. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Margolis SS, Perry JA, Weitzel DH, et al: A role for PP1 in the Cdc2/Cyclin B-mediated positive feedback activation of Cdc25. Mol Biol Cell. 17:1779–1789. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Ray G, Dhar G, Van Veldhuizen PJ, et al: Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry. 45:3703–3713. 2006. View Article : Google Scholar
27.	Cheng Y, Qiu F, Ye YC, et al: Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys. 490:70–75. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Hsu YL, Kuo PL, Lin LT and Lin CC: Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells. J Pharmacol Exp Ther. 313:333–344. 2005. View Article : Google Scholar
29.	Guruvayoorappan C and Kuttan G: Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacol Immunotoxicol. 30:711–727. 2008. View Article : Google Scholar